41O.F Outlook Therapeutics, Inc.
- Market cap
- EUR 96.2M
- P/E
- -
- P/B
- 38.57x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 41O.F undervalued?
Graham numberThe Graham number of Outlook Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Outlook Therapeutics, Inc. fundamental analysis
No fundamental analysis for Outlook Therapeutics, Inc. yet.
Outlook Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Ce…
Full company profileOutlook Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Outlook Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 1.41M | -1.43M |
| Gross Profit | - | - | 0.00 | 57.2K | -1.69M |
| Operating Income | -63.1M | -53.1M | -71.7M | -67.1M | -51.1M |
| EBITDA | -64.4M | -56.4M | -72.1M | -63.6M | -51.0M |
| Net Income | -66.1M | -59.0M | -75.4M | -62.4M | -63.8M |
| EPS | -5.81 | -4.53 | -3.15 | -1.16 | -0.34 |
| Balance Sheet | |||||
| Total Assets | 28.5M | 32.3M | 28.8M | 18.6M | 26.2M |
| Total Liabilities | 19.8M | 46.7M | 102M | 50.8M | 36.6M |
| Shareholders' Equity | 8.74M | -14.4M | -73.1M | -32.2M | -10.4M |
| Cash & Short-term Investments | 17.4M | 23.4M | 14.9M | 8.08M | 11.2M |
| Cash Flow | |||||
| Operating Cash Flow | -56.7M | -43.0M | -68.8M | -51.8M | -58.4M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -56.7M | -43.0M | -68.8M | -51.8M | -58.4M |
| Ratios | |||||
| ROE | -756.0% | - | - | - | - |
| ROA | -231.5% | -182.6% | -261.5% | -335.9% | -243.6% |
| Net Profit Margin | - | - | - | -4,416.2% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Outlook Therapeutics, Inc. dividends
Outlook Therapeutics, Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 1:20 on Mar 14, 2024.
Who owns Outlook Therapeutics, Inc.
- Insiders 12.64%
- Institutions 25.55%
- Public & others 61.81%
- Shares outstanding 243M
- Free float 177M
Outlook Therapeutics, Inc. company profile
- Company name
- Outlook Therapeutics, Inc.
- Ticker
- 41O.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Fiscal year end
- September
- Address
- 111 S. Wood Avenue, Iselin, NJ, United States, 08830
- Phone
- 609 619 3990
- Website
- outlooktherapeutics.com
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Outlook Therapeutics, Inc. management
7- Mr. Robert Charles JahrPresident, CEO & Director · born 1973
- Mr. Kevin LundquistCFO, Treasurer, Principal Financial Officer & Principal Accounting Officer · born 1968
- Mr. Joel PrieveSenior Vice President of Licensing and M&A
- Dr. Surendra Sharma M.D.Senior Vice President of Medical Affairs
- Dr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development & Regulatory Affairs
- Mr. Jedd ComiskeySenior VP - Head of Europe
- Mr. Greg DiPasqualeChief Commercial Officer